Furosemide Stress Test to Predict Successful Liberation From RRT

Centre Hospitalier Universitaire Vaudois52 enrolled

Overview

The proposed study will evaluate if a standardised dose of furosemide administered in the 12 hours after RRT liberation can predict successful liberation in critically ill patients. The dose that will be administered is in accordance with the prescribing information.

Response to furosemide administration is commonly used in clinical practice to assess a patient's potential for RRT liberation. However, this administration is not standardized and practices varies greatly. Rapid recognition of unsuccessful RRT liberation is crucial to avoid further complications such as fluid overload or acid-base and electrolyte disorders. The FST corresponds to the intravenous administration of 1 mg/kg (1.5 mg/kg in previously exposed patients) of furosemide and the assessment of resulting diuresis in the following two hours. FST is able to predict progression from AKI stage I and II to stage III with a high sensitivity (87.1%) and specificity (84.1%), area under the ROC curve 0.87. However, the ability of FST to predict RRT liberation has never been formally assessed.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Acute Kidney Injury

Interventions

Furosemide stress testDRUG

The FST corresponds to the intravenous single-dose administration of 1 mg/kg (1.5 mg/kg in previously exposed patients) of furosemide and the assessment of resulting diuresis in the following two hours. In the 12 hours following the first RRT liberation, a FST will be performed. The test will be considered positive if urinary output is ≥200 mL in the two hours following furosemide administration.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Receiving continuous or intermittent RRT for AKI * Having an indwelling urinary catheter * Clinical decision by physician in charge to attempt RRT liberation * lnformed consent signed by the patient himself / legal representative or authorization received from independent physician Exclusion Criteria: * Electrolyte disturbances or hemodynamic instability precluding the use of furosemide (sodium \> 155 mmol/L and/or potassium \< 3.0 mmol/L and/or metabolic alkalosis \> 7.50 and/or mean arterial pressure \< 60 mmHg) * Known furosemide allergy * Urine output ≥ 100 mL/h for at least two hours * Recent (\< 24 hours) FST * Known end-stage chronic renal disease at ICU admission * Withdrawal of life support decision taken before inclusion * Patient already participating in conflicting research study * Patient having already participated in this current study * Any other contraindication of furosemide

Locations (1)

Centre Hospitalier Universitaire Vaudois

Lausanne, Canton of Vaud, Switzerland

Outcomes

Primary Outcomes

Successful liberation of RRT within 72 hours after FST

No renal replacement therapy administered

Time frame: within 72 hours

Secondary Outcomes

Successful liberation of RRT at ICU discharge

No renal replacement therapy administered

Time frame: At time of ICU discharge, assessed up to 90 days post inclusion

Successful liberation of RRT at hospital discharge

No renal replacement therapy administered

Time frame: At time of hospital discharge, assessed up to 90 days post inclusion

Adverse events associated with the intervention

(electrolyte disturbances, hypotension)

Time frame: within 6 hours

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.